** Insulet's PODD.O shares up 1% to $263.34 on Mon after medical device maker announces C-suite change and provides bullish 2025 rev outlook
** Acton, Massachusetts-based firm early Mon said Ashley McEvoy appointed as CEO and board member, effective immediately
** Former CEO Jim Hollingshead agreed to cease his employment and entered into consulting arrangement to facilitate a smooth transition, co said
** McEvoy was previously exec VP and global chair of Johnson & Johnson's JNJ.N medtech business
** Co also said expects to surpass prior Q1 rev forecast and plans to raise full-year guidance
** BTIG reiterated its 'buy' rating on PODD ($310 PT), saying McEvoy is highly qualified and well-suited for the CEO role given her extensive experience in both the medtech and diabetes care sectors
** In Feb, co posted Q4 top line beat driven by strong demand for its Omnipod insulin pumps, and forecasted current-qtr rev to grow 22%-25% y/y and for 2025 rev to increase 16%-20% from 2024 figure of $2.1 bln
** Co slated to release Q1 results on May 8, after market close. In light of CEO transition, co postponed previously planned Jun 5 investor day event and intends to reschedule
** Including move on the session, PODD shares up ~1% YTD. Stock was trading around $170 a year ago
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.